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Abstract GSK961081 (batefenterol) is a novel bifunc-
tional molecule composed of a muscarinic antagonist and a
b2-agonist. The aims of this substudy were (1) to charac-
terize the population pharmacokinetics (PK) and pharma-
codynamics (PD) of GSK961081 in patients with
moderate-to-severe chronic obstructive pulmonary disease
(COPD); and (2) to investigate the relationship between
systemic exposure to GSK961081 and key cardiac-related
safety parameters. Three once-daily doses (100, 400, and
800 lg) and three twice-daily doses (100, 200, and 400 lg)
of GSK961081 DISKUS were investigated. A two-com-
partment disposition PK model with first-order absorption
adequately described the plasma GSK961081 concentra-
tion–time data. An empirical maximum-effects PD model
adequately described the forced expiratory volume in 1 s
(FEV1) response relationship with the covariate baseline
FEV1 on day 1. No clear relationships between
GSK961081 plasma drug levels and cardiac-related safety
parameters were apparent. The PK and PD models will be
used to guide the dose selection and development of
GSK961081 in patients with COPD.
Key Points
A two-compartment model accurately described the
distribution of the GSK961081 concentration–time
data.
The pharmacokinetic and pharmacodynamic models
described the observed data well, with adequate
goodness-of-fit diagnostic plots.
A muscarinic antagonist and a b2-agonist in one
molecule may potentially lead to the development of
another regimen to support the current strategy of
combining b2-agonists and anti-muscarinics as
inhaled bronchodilators for treatment of chronic
obstructive pulmonary disease.
1 Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease of the respiratory system and is a major
cause of morbidity and mortality worldwide [1]. The pri-
mary aims of the pharmacological treatment of chronic,
stable COPD are to optimize lung function, reduce exac-
erbations, and improve exercise tolerance and quality of
life [2, 3]. Current treatment strategies include the use of
b2-agonist (BA) therapy and anti-muscarinic therapy
delivered as inhaled bronchodilators [2].
GSK961081 (batefenterol) is a novel bifunctional
molecule composed of both a muscarinic antagonist (MA)
and a BA separated by an inert linker portion [4]. The
combination of an MA with a BA results in greater bron-
chodilation in the airways than either component alone [5].
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The bifunctional nature of GSK961081 has previously been
demonstrated in vitro [6] and in vivo [7].
A phase IIb clinical trial of GSK961081 reported an
improvement in the trough forced expiratory volume in 1 s
(FEV1) of 155–277 mL after 28 days of treatment [8].
GSK961081 has a rapid onset of action and was well tol-
erated [8, 9]. The safety of adding short-acting bron-
chodilators (SABAs) to a GSK961081 treatment regimen
was assessed and showed that SABAs may be used as a
rescue therapy on top of muscarinic b2-agonist (MABA)
therapy [10].
A single compound with MABA activity, such as
GSK961081, has advantages over the use of two separate
compounds. As a single pharmacokinetic (PK) profile
exists for both pharmacological activities, there is the
potential to maximize the synergy between the two
mechanisms. The technical and clinical development
pathway is also simpler for a single compound than for a
co-formulation of two separate compounds [11, 12].
PK and pharmacodynamic (PD) modelling techniques
are a recognized method used to determine the optimal
dose and dose regimen of drugs under development [13,
14]. The aim of this substudy was to characterize the
population PK and PD of GSK961081 in patients with
moderate-to-severe COPD; the primary results from the
study (GlaxoSmithKline study number MAB115032;
http://www.clinicaltrials.gov registration number
NCT01319019) have been published elsewhere [8]. The
resulting data will be used to help define the most appro-
priate dose and dose interval in future clinical trials of
GSK961081. Long-acting b2-agonists have been associated
with cardiac-related effects, showing potential to increase
the heart rate and cause corrected QT interval (QTc) pro-
longation and ventricular arrhythmias in patients with
COPD [15, 16]. Therefore, we also investigated the rela-
tionship between systemic exposure to GSK961081 (con-




This PK and PD assessment of GSK961081 was part
of a 4-week, multicenter, randomized, double-blind,
double-dummy, placebo- and salmeterol-controlled
parallel-group study, which has been published else-
where [8] (GlaxoSmithKline study number
MAB115032; http://www.clinicaltrials.gov registration
number NCT01319019). In this substudy, we report the
PK and PD analyses of the active treatment,
GSK961081. Three once-daily doses (100, 400, and
800 lg) administered in the morning and three twice-
daily doses (100, 200, and 400 lg) of GSK961081
DISKUS were investigated.
2.2 Study Patients
Male and female outpatients aged C40 years who were
either current or former smokers with a smoking history of
C10 pack-years were recruited. The patients had a clinical
diagnosis of moderate-to-severe stable COPD, based on
spirometric normative values according to the National
Health and Nutritional Examination Survey III [17] (post-
bronchodilator FEV1/forced vital capacity\70 and FEV1
C30 and B70 % predicted). Patients receiving a stable dose
of inhaled corticosteroids were eligible for enrollment.
Patients diagnosed with asthma were excluded.
The study was approved by the medical ethics com-
mittees at the participating centers, and all participants
gave their written informed consent for participation. The
study was conducted according to the Declaration
of Helsinki [18] and Good Clinical Practice guidelines
[19]. The characteristics of the study population are shown
in Table 1.
2.3 Study Assessments
Spirometry FEV1 was performed in all patients, using a
Vitalograph (Biomedical Systems, Brussels, Belgium). The
day 29 trough FEV1 was defined as the mean of the 11 and
12 h measurements after the evening dosing on day 28.
PK blood sampling was performed in a subset of patients
at overnight sites. On day 28, following administration of
both the morning and the evening doses, blood samples were
collected at 1 h to 0 min before dosing and then at 0–30 min,
30 min–2 h, 2–6 h, and 6–11 h after dosing.
PK analysis of GSK961081 concentrations was per-
formed using a validated high-performance liquid
Table 1 Demographic characteristics
Characteristic PD and PK/PD PK model-building
n 347 47
Age (years)a 63 ± 8.2 63 ± 8.9
Weight (kg)a 76 ± 14 72 ± 13
Height (cm)a 171 ± 8.5 169 ± 7.7
Male (%) 65 62
Current smoker (%) 49 49
Concurrent ICS use (%) 58 53
Baseline FEV1 on day 1 (L)
a 1.31 ± 0.46 1.36 ± 0.42
FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid,
PD pharmacodynamics, PK pharmacokinetic(s)
a The data are presented as means ± standard deviations
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chromatography and mass spectrometry method with a
lower limit of quantification (LLOQ) of 25 pg/mL. The
detailed bioanalytical methodology has been reported
previously [4]. PK samples obtained from patients in the
placebo and salmeterol treatment groups were not
analyzed.
2.4 Pharmacokinetic and Pharmacodynamic
Analyses
Plasma concentrations of GSK961081, expressed as natural
logarithms and trough FEV1 values, were modelled using
NONMEM version 7 software (ICON Developments
Solutions, Dublin, Ireland). The first-order conditional
estimation method with interaction was used for the PD
model, and all data were used in the model-building. The
Monte Carlo importance sampling method was used for the
PK model. The M3 methodology was used to maximize the
likelihood for the plasma GSK961081 data, treating those
data that were below the LLOQ as censored for the PK
model [20]. The percentage of PK data below the LLOQ
was [50 % for all GSK961081 treatments, except for
800 lg once daily on days 1 and 28, and 400 lg twice
daily on day 28. Therefore, the PK model-building data set
comprised data from the 800 lg once-daily and 400 lg
twice-daily treatment groups on day 28 only, of which 30
and 27 % of the data, respectively, were below the LLOQ.
The full PK data set comprised data from all GSK961081
treatment groups.
Model selection was based on the objective function
values computed by NONMEM, goodness-of-fit graphical
checking, and physiological plausibility of parameters.
Potential covariates were investigated using a stepwise
forward addition and backward elimination approach for
the PD model only [21]. The covariates baseline FEV1 on
day 1, age, weight, sex, height, smoking status, and inhaled
corticosteroid use were investigated. A p value of\0.01
was used in the forward step and a p value of\0.001 was
used in the backward step. Simulation-based diagnostics
and re-estimation methods were used to evaluate the per-
formance of the PK and PD final models [21].
Relationships between selected PD endpoints [including
the glucose level, heart rate, QT interval corrected for the
heart rate using Fridericia’s correction (QTcF), and
potassium level] and systemic exposure to GSK961081
[the maximum plasma drug concentration (Cmax)] were
explored graphically. Placebo data were plotted using a
value of 0 pg/mL, and GSK961081 values below the




A total of 405 GSK961081 PK samples from 47 patients
were included in the model-building PK data set. This
comprised data from the 800 lg once-daily and 400 lg
twice-daily treatment groups only (see Sect. 2). A two-
compartment disposition model (ADVAN4 TRANS4) with
first-order absorption was adequate to describe the plasma
GSK961081 concentration–time data (Table 2). Interindi-
vidual variability could be estimated reliably for the
apparent elimination clearance. Covariates were not
included in the PK model, because of the limited data set.
The PK model described the observed data well, with
adequate goodness-of-fit diagnostic plots (Fig. 1). A visual
predictive check of the model showed no model misspeci-
fications and good simulation properties for both the model-
building data set and the full data set (Fig. 2). The full data
set comprised 1112 GSK961081 PK samples from 128
patients (see Sect. 2). Bootstrapping confirmed the reliability
of the PK model parameter estimates (data not shown).
Table 2 Pharmacokinetic (PK)
model parameters
PK parameter Log estimate RSE (%) 95 % CI
CL/F (L/h) 6.85 1.72 6.62 to 7.08
V2/F (L) 6.26 3.71 5.82 to 6.72
KA (h-1) -0.89 -15.2 -1.16 to -0.625
V3/F (L) 9.97 2.90 9.40 to 10.5
Q (L/h) 7.25 2.17 6.94 to 7.56
Interindividual variability CL/F 0.594 0.137 0.325 to 0.863
Proportional residual error 0.365 0.0175 0.331 to 0.399
CI confidence interval, CL/F apparent clearance, KA absorption rate constant, Q intercompartmental
clearance, RSE relative standard error, V2/F apparent central volume of distribution, V3/F apparent
peripheral volume of distribution
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3.2 Pharmacodynamics
A total of 347 trough FEV1 samples from 347 patients
were included in the PD data set. A summary of patient
demographics and clinical characteristics at screening was
published in the primary paper (see the GSK961081 and
placebo treatment groups only) [8]. An empirical maxi-
mum-effects (Emax) model (Eq. 1) was adequate to
describe the FEV1 response relationship (Table 3), with
the baseline FEV1 on day 1 as a covariate (Eq. 2):
Effect ¼ ðE0  COVÞ þ Emax Total Dose
Total Doseþ ED50 ð1Þ
COV ¼ CON Baseline FEV1 on Day 1
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Fig. 1 Goodness-of-fit of the final pharmacokinetic model. a Log-
arithmic plasma GSK961081 concentrations on day 28 versus pop-
ulation predictions. b Logarithmic plasma GSK961081
concentrations on day 28 versus individual predictions. c Conditional
weighted residuals versus population predictions. d Conditional
weighted residuals versus time. The solid lines indicate the identity
lines, and the dashed lines indicate the loess smooths
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where Emax is the trough FEV1 at the maximum effect, E0
is the FEV1 at zero dose, ED50 is the dose producing 50 %
of the maximum effect, and CON is the baseline FEV1
covariate effect.
The PD model described the observed data well, with
adequate goodness-of-fit diagnostic plots (Fig. 3). A visual
predictive check of the model showed no model misspec-















































































































































































































Fig. 2 Visual predictive check
of the final pharmacokinetic
model, showing the logarithmic
plasma GSK961081
concentrations versus time on
day 28 for a 100 lg twice daily,
b 200 lg twice daily, c 400 lg
twice daily, d 100 lg once
daily, e 400 lg once daily, and
f 800 lg once daily. The
horizontal lines indicate the
lower limits of quantification for
the pharmacokinetic assay, the
solid lines indicate the
population means, the dashed
lines indicate the 95 %
prediction intervals, the dotted
lines indicate the observed
means, and the dashed-dotted
lines indicate the upper limits of
the observed 95 % prediction
intervals. Shaded areas indicate
the 95 % confidence interval of
the prediction interval. TRT
treatment
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agreement with the primary endpoint analysis [8]. Boot-
strapping confirmed the reliability of the PD model
parameter estimates (data not shown).
3.3 Relationship Between Exposure and Safety
Endpoints
The PK/PD analyses evaluated the relationship between
key safety endpoints and systemic exposure to
GSK961081. No clear relationships between maximum
glucose, heart rate, QTcF and minimum potassium versus
individual observed GSK961081 plasma drug levels (Cmax)
were apparent (Fig. 5). It should be noted that these anal-
yses were limited by high variability in the placebo
response and a large number of patients with a Cmax below
the LLOQ. Exploratory PK/PD analysis by way of gener-
alized linear models did not show any significant rela-
tionships (data not shown). Similar evaluation of weighted
mean changes in glucose levels, heart rate, QTcF, and
potassium levels (0–4 h) from baseline versus individual
observed GSK961081 Cmax values also showed no clear
relationships with safety endpoints (data not shown).
4 Discussion
This substudy is the first to report the population PK and
PD of GSK961081 in patients with moderate-to-severe
COPD. This information is important in the guidance of
dose selection and subsequent clinical development of this
novel compound. A two-compartment model accurately
described the distribution of the GSK961081 concentra-
tion–time data. This substudy had a small number of
patients because of limited PK sampling and a large
number of non-quantifiable data. Due to the limited data
available, covariates were not included in the PK model.
We followed the recommendations of Ribbing and Jonsson
[22], who suggested that stepwise selection of covariates or
significance testing of covariates should not be used in data
sets of less than 50–100 subjects.
An Emax model described the trough FEV1 response on
day 29. The primary study showed that there was only a
small increase in the trough FEV1 from 400 to 800 lg, and
concluded that a total daily dose of 400 lg may be the
optimal dose [8]. These results are consistent with the final
PD model reported here. As PK/PD models are an impor-
tant tool in drug development [13, 14], our PK/PD mod-
elling results with GSK961081 will aid dose selection for
further studies of this novel compound in patients with
COPD.
There were some limitations to this substudy. The
number of different treatment doses investigated was small,
and once-daily and twice-daily doses were combined for
the PD analysis. However, there was no apparent influence
of dosing regimen on the PD model, indicating that there
was no apparent difference between once-daily and twice-
daily dosing for the primary endpoint of the day 29 trough
FEV1—a finding also reported in the primary publication
[8].
Long-acting b2-agonists have been associated with
cardiac-related effects [15, 16]. Over the doses of
GSK961081 assessed in the current study, PK/PD analy-
ses revealed no apparent relationship between individual
Cmax values and any increase in the heart rate or QTcF.
Furthermore, no clear relationship with blood potassium
or glucose values was observed. The range of Cmax values
in this substudy was limited, and we were not able to
quantify this parameter in all patients. However, these
results support the safety findings reported in the primary
publication [8] that GSK961081 has no effect on glucose
levels, potassium levels, heart rate, or blood pressure. In
addition, although GSK961081 was associated with pro-
longation of various QTc intervals (by 3–5 ms, in com-
parison with placebo or salmeterol), there was no
apparent dose response [8]. A previous study that inves-
tigated GSK961081 at a dose of 1200 lg once daily
demonstrated that there was no prolongation of the QT
interval [23]. Collectively, these data suggest that at the
wide range of doses evaluated to date, GSK961081 may
Table 3 Pharmacodynamic (PD) model parameters
PD parameter Estimate RSE (%) 95 % CI
Emax (L) 0.293 14.9 0.207–0.379
ED50 (lg) 152 50.2 2.45–302
Intercept for E0 (L) 0.0650 32.8 0.0233–0.107
Baseline (L) 19.0 36.9 5.24–32.8
Proportional residual error 0.204 30.8 0.0809–0.327
CI confidence interval, E0 FEV1 at zero dose, ED50 dose producing
50 % of the maximum effect, Emax trough FEV1 at the maximum
effect, RSE relative standard error
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not be expected to induce cardiac-related effects; how-
ever, the current data are preliminary, and longer-term
studies are required in patients with COPD to fully
evaluate the tolerability profile of this compound.
COPD treatment guidelines recommend the use of
combination bronchodilator therapy if patients remain
symptomatic on a single bronchodilator [2]. Preclinical
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Fig. 3 Goodness-of-fit of the final pharmacodynamic model.
a Trough forced expiratory volume in 1 s (FEV1) values on day 29
versus population predictions. b Trough FEV1 values on day 29
versus individual predictions. c Conditional weighted residuals versus
population predictions. d Conditional weighted residuals versus total
daily doses. The solid lines indicate the identity lines, and the dashed
lines indicate the loess smooths
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bronchodilators with different mechanisms of action has
demonstrated a significant synergistic interaction in the
bronchorelaxant response of human airways [24–27]. As a
bifunctional molecule composed of both an MA and a BA,
GSK961081 is postulated to have an advantage over
combinations using two separate compounds, as the phar-
macological activities are from a single molecule, thus
ensuring co-localization at the site of action, potentially
increasing the degree of bronchodilation with similar side
effects.
5 Conclusion
The PK and PD models described in this substudy will be
used as tools to guide the dose selection and clinical
development of GSK961081 in patients with COPD. This
novel compound combines two active moieties—an MA
and a BA—in one molecule and may potentially lead to the
development of another regimen to support the current
strategy of combining b2-agonists and anti-muscarinics as
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Fig. 4 Visual predictive check of the final pharmacodynamic model.
a Day 29 trough forced expiratory volume in 1 s (FEV1) values
versus total daily doses; the white circles indicate observed data, the
solid line indicates the population means, and the dashed lines
indicate the 95 % prediction intervals. b Day 29 placebo-corrected
changes from baseline trough FEV1 values versus total daily doses;
the black circles indicate once-daily dosing, the black triangles
indicate the twice-daily dosing least squares means (with 95 %
confidence intervals) from Wielders et al., the solid line indicates the
pharmacodynamic model population medians, and the dashed lines
indicate the pharmacodynamic model 95 % prediction intervals
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(regression plots) from 0 to 4 h
on day 1 (left-hand panels) and
day 28 (right-hand panels) for
a maximum glucose level,
b maximum heart rate,
c maximum QT interval
corrected for the heart rate using
Fridericia’s correction (QTcF),
and d maximum potassium
level. The white circles indicate
once-daily dosing, and the
crosses indicate twice-daily
dosing. For Cmax,
placebo = 0 pg/mL,
NQ = LLOQ/2,
LLOQ = 25 pg/mL (indicated
by the dashed vertical lines).
bpm beats per minute,
LLOQ lower limit of
quantification, NQ not
quantifiable
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potential role of an MABA molecule may be as part of a
triple COPD therapy delivered via a single inhaler [10].
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